Management
Set your eyes on us! We are a team of seasoned ophthalmology drug development and market experts exploring the world of water-free therapies to develop transformational ocular therapies. Our vision now is to revolutionize the treatment of diabetic retinopathy drug products developed for topical administration, to preserve eyesight in millions of patients around the globe.
Since December 2019, Novaliq has a strategic cooperation with Bausch + Lomb. Bausch has received exclusive rights to develop, manufacture and commercialize NOV03 (perfluorohexyloctane) in USA and Canada.
In May 2023 MIEBO™ (perfluorohexyloctane ophthalmic solution; formerly known as NOV03) was approved for the treatment of the signs and symptoms of dry eye disease (DED) in the USA. MIEBO™ is the first and only FDA-approved treatment for DED that directly targets tear evaporation. Please refer to www.miebo.com for more information and MIEBO™ prescription information. Approval in Canada is expected in 2024 by Bausch + Lomb.
In 2023 Harrow acquired the U.S. and Canadian commercial rights for VEVYE™ (cyclosporine ophthalmic solution, formerly known as CyclASol®) 0.1%, a patented, non-preserved, ophthalmic solution prescription drug based on Novaliq’s proprietary EyeSol® water-free technology. VEVYE™ (cyclosporine ophthalmic solution) 0.1% is the first and only cyclosporine ocular therapy to treat both the signs and symptoms of dry eye disease and was approved by FDA in May 2023. Please refer to www.vevye.com for more information and VEVYE™ prescription information.
In China, Novaliq has a strategic cooperation with Jiangsu Hengrui Pharmaceuticals since November 2019.
Hengrui has received exclusive rights to develop, manufacture and commercialize NOV03 and CyclASol® for the treatment of dry eye disease in China.
In Japan Novaliq partners with Senju Pharmaceutical Co., Ltd., a researched-based Japanese pharmaceutical company focusing the field of ophthalmology, to develop, manufacture, and commercialize NOV03 (perfluorohexyloctane ophthalmic solution), a first-in-class, preservative-free treatment for signs and symptoms of dry eye disease.
In April 2019, Novaliq has founded Betaliq Inc., Tampa, USA in collaboration with BLP Management Group, LLC. Betaliq develops the ophthalmic beta-blocker BTQ 1902 using Novaliq’s proprietary EyeSol® water-free technology. In the US Phase 2 study BTQ-1902 met the study goal of statistical non-inferiority to marketed Timolol 0.5% indicating a strong likelihood of achieving a positive outcome in the final Phase 3 study. BTQ-1902 had an excellent safety profile and was well tolerated. Requirements for NDA filing was confirmed by FDA written correspondence. Betaliq plans to enter Phase 3 with BTQ-1902 (timolol in EyeSol®) soon.
Our journey as a company started by developing a first-in-class, preservative-free topical eye treatment and tear film stabilizer based on perfluorohexyloctane.
These novel water-free products are clinically validated by significant improvement in signs and symptoms in patients with evaporative dry eye disease and Meibomian gland disfunction (MGD) in a number of clinical trials. This new class of water-free products was initially CE certified in 2013 and are successfully commercialized in Australia/New Zealand by AFT Pharmaceuticals and in Europe by Ursapharm.
Ursapharm is one of the leading EU ophthalmic players.
In October 2015, EvoTears® (perfluorohexyloctane) entered the EU market. EvoTears® has been successfully launched in 17 European countries incl Germany, France, UK, Spain, Italy, Benelux, Poland and Switzerland.
In some countries the product is also known under other brand names: HYLO LIPID™ (France), Hycosan Shield™ (UK).
In January 2020 the novel product EvoTears™ OMEGA with algae derived omega-3 to alleviate irritated eyes and lid margins has been launched in Germany and other countries in Europe.
AFT Pharmaceuticals is a New Zealand-based pharmaceutical company listed in ASX and NZX, and Novaliq’s partner for the commercialization of NovaTears® (perfluorohexyloctane) and NovaTears®+Omega-3 in Australia and New Zealand.
AFT is a leader in the lubricating eyecare category in Australia with sales growth from the NovaTears® family contributing to its growth.
In Australia NovaTears® is PBS listed since September 2018. The PBS Schedule lists all the medicines available to be dispensed to patients at a government-subsidized price.
Academic partners
Novaliq collaborates with leading scientific partners
Prof. Dr. med. Claus Cursiefen in the field of ophthalmic drug delivery for the anterior segment of the eye with special focus on dry eye disease.
Prof. Heping Xu, MD, PhD, in the field of retina diseases.
Dr. Ilva Rupenthal in the field of drug delivery technologies and ocular therapeutics.
Prof. Dr. med. Johannes Wohlrab in the field of penetration and dermatology.
Prof. Dr. Wolfgang Frieß in the field of protein formulation.
Prof. Gordon Tiddy and Dr. Robin Curtis in the field of basic research in formulation sciences.